Oxyrase

Executive Summary

Oxyrase, founded in 1987 and headquartered in Mansfield, United States, is a privately-held biotechnology company specializing in anaerobic culture and oxygen removal solutions. The company is best known for its gold-standard Pre-Reduced Anaerobically Sterilized (PRAS) media, OxyPlates, and enzyme systems, which are widely used in clinical, research, and industrial laboratories for the cultivation of anaerobic microorganisms. Beyond traditional diagnostics and infectious disease applications, Oxyrase has expanded its technology into biological preservation and niche markets such as winemaking, leveraging its proprietary oxygen-scavenging enzymes. Despite being a established player with a strong product portfolio, the company operates in a relatively niche but essential segment of the microbiology market. With no disclosed funding history or valuation, Oxyrase appears to be self-sustained, relying on steady revenue from its specialized customer base. The company's growth potential lies in further penetrating adjacent markets (e.g., food safety, pharmaceuticals) and developing novel formulations for emerging anaerobic research needs. Its long track record and proprietary know-how provide a defensible competitive position, though limited visibility into financials and pipeline makes assessment challenging.

Upcoming Catalysts (preview)

• Q2 2026Launch of Next-Generation OxyPlate for Fastidious Anaerobes70% success
• Q3 2026Strategic Partnership for Food Safety Anaerobic Testing50% success
• Q4 2026FDA Clearance for Expanded Use of Enzyme System in Medical Device Preservation60% success